Wilson Sonsini Goodrich & Rosati advised Acumen Pharmaceuticals on the deal. Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Goodwin Procter LLP advised Centessa Pharmaceuticals on the deal. Centessa Pharmaceuticals, a clinical-stage company employing its innovative asset-centric business model...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Fenwick & West LLP advised Day One Biopharmaceuticals on the deal. San Francisco-based Day One Biopharmaceuticals, a Phase 2 biotech...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Day One Biopharmaceuticals on the deal. Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies...
You must be a Standard 1 Year member to access this content.
